Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Trial of Tumor Neoantigen Vaccine
NCT04087252Phase 1Unknown
- Sponsor
- Henan Cancer Hospital
- Start
- Sep 2019
- Primary completion
- Oct 2021
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial in cancer, sponsored by Henan Cancer Hospital. Primary endpoint: Safety of the immunogenic personal neoantigen vaccine at 1.5 years. Status: unknown.
02
Conditions
cancer
Beyond the preview
Go deeper on NCT04087252.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04087252.